Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLitt, John-
dc.contributor.authorBooy, Robert-
dc.contributor.authorBourke, Debra-
dc.contributor.authorDwyer, Dominic E-
dc.contributor.authorLeeb, Alan-
dc.contributor.authorMcCloud, Philip-
dc.contributor.authorStein, Alicia N-
dc.contributor.authorWoodward, Michael M-
dc.contributor.authorCunningham, Anthony L-
dc.identifier.citationHuman Vaccines & Immunotherapeutics 2020; 16(12): 3081-3089-
dc.description.abstractHerpes zoster (shingles) is a painful condition resulting from reactivation of latent varicella zoster virus (VZV). The Australian National Shingles Vaccination Program (commenced November 2016) provides free herpes zoster vaccination for eligible adults aged 70 years, with a 5-year catch-up program (until October 2021) for adults aged 71-79 years. Patterns and impact of the program were evaluated by analysis of vaccine distribution and delivery data and specific antiviral prescription data from the Pharmaceutical Benefits Scheme. During the first 2 years, uptake of funded live attenuated shingles vaccine ZOSTAVAX® (Zoster Virus Vaccine Live; ZVL) was high across the ongoing and catch-up programs. Before program implementation (2006-2016), herpes zoster coded antiviral prescription rates increased by 2.2% per year (95% CI: 1.5, 2.9) in the 70-79 years age group. In the two years since program launch, herpes zoster antiviral prescription rates declined substantially in this age group, by an average of 13.6% per year (95% CI: 1.5, 24.2). These results indicate that the National Shingles Vaccination Program has been highly successful in vaccinating a considerable proportion of Australian adults aged 70-79 years against herpes zoster and suggest that vaccine uptake was associated with decreased incidence of herpes zoster.-
dc.subjectHerpes zoster-
dc.subjectherpes zoster vaccine-
dc.subjectpostherpetic neuralgia-
dc.subjectvaricella zoster virus-
dc.subjectzoster virus vaccine live-
dc.titleEarly impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine.-
dc.typeJournal Article-
dc.identifier.journaltitleHuman Vaccines & Immunotherapeutics-
dc.identifier.affiliationDiscipline of General Practice College of Medicine and Public Health, Flinders University, Adelaide, Australiaen
dc.identifier.affiliationNSW Health Pathology - Institute for Clinical Pathology and Medical Research, Westmead Hospital and the University of Sydney, Sydney, Australiaen
dc.identifier.affiliationMedical Department, Seqirus (Australia) Pty Ltd, Parkville, Australiaen
dc.identifier.affiliationNational Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney, Sydney, Australiaen
dc.identifier.affiliationFaculty of Medicine and Health, The Westmead Institute for Medical Research, Westmead, Australiaen
dc.identifier.affiliationThe University of Sydney, Sydney, Australiaen
dc.identifier.affiliationCentre for Virus Research, University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationHelath Economics, Seqirus (Australia) Pty Ltd, Parkville, Australiaen
dc.identifier.affiliationMcCloud Consulting Group, Belrose, Australiaen
dc.identifier.affiliationIllawarra Medical Centre, Ballajura, Australiaen
dc.identifier.affiliationDepartment of Aged and Continuing Care, Austin Health, Heidelberg, Victoria, Australia-
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.fulltextNo Fulltext- Care- Medicine-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 27, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.